PepGen Inc.
PEPGDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
3
Next Catalyst
Aug 6, 2026
TomorrowMarket Overview
Stock performance and key metrics
3 upcoming, 0 past
PEPG Earnings Report
EPS Est: $-0.30 | FQ end 2026-06
PGN-EDODM1 Phase 2 Est. Readout
Primary completion for PGN-EDODM1 trial (NCT06667453) in Myotonic Dystrophy 1
Source1 more catalyst beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How PEPG's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
PGN-EDODM1 | Phase 2 | Myotonic Dystrophy 1 | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in PepGen Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in PepGen Inc.'s (PEPG) pipeline across Phase 2. Its lead program is PGN-EDODM1 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is PepGen Inc.'s next FDA catalyst?→
PepGen Inc.'s (PEPG) next tracked catalyst is a Earnings expected August 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track PEPG biotech catalysts?→
Add PEPG to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow PepGen Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.